Sai Parenteral’s IPO to open on March 24; to raise ₹285 crore via fresh issue

Sai Parenteral’s (SPL), a diversified pharmaceutical formulation company, has filed its Red Herring Prospectus (RHP) with SEBI for its proposed initial public offering (IPO).

The IPO comprises a fresh issue of up to ₹285 crore and an offer-for-sale of up to 3,157,880 equity shares. The price band was fixed at ₹372-392 per share. It will be launched on March 24.

“The proposed IPO represents an important milestone in SAI’s growth journey. It reflects the progress we have made as an organisation and provides us with an opportunity to further accelerate our strategic objectives,’’ Anil KK, Chairman and Managing Director, SPL, said in a release on Tuesday.

Fund expansion

“The proceeds from the IPO will support the next phase of our expansion, particularly in strengthening our global formulations business and expanding our Contract Development and Manufacturing Organisation (CDMO) capabilities across both injectable products and oral solid dosage formulations,’’ he added.

The investments were intended to enhance the company’s ability to serve global pharmaceutical partners and expand its presence in regulated markets.

Published on March 17, 2026